Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri maintains an Overweight rating on SI-BONE (NASDAQ:SIBN) but lowers the price target from $26 to $25.

May 07, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley maintains an Overweight rating on SI-BONE but lowers the price target from $26 to $25.
While the reduction in price target could suggest a slightly less optimistic view on SI-BONE's short-term price potential, the maintenance of an Overweight rating indicates a continued positive outlook on the company's fundamentals. This mixed signal might lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the sustained positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100